Insights and Challenges in Advancing HER2+ Breast Cancer Care
Experts review groundbreaking advancements in HER2+ breast cancer treatment, covering curative strategies, metastatic challenges, and the need for ongoing innovation to enhance patient outcomes.
EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer
EP: 3.HER2+ Breast Cancer: Anthracycline Considerations
EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends
EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer
EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer
EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer
EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases
EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights
EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges
EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer
EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
The panel concludes the discussion on HER2-positive breast cancer treatment, emphasizing significant advances in adjuvant, neoadjuvant, and metastatic settings. Isaacs highlights exploring chemotherapy-free regimens for hormone receptor-positive, HER2-positive patients. Sharma underscores the need for further optimization in endocrine therapy and CDK4/6 inhibitor studies. McArthur expresses excitement about the unprecedented era of successful drug development, focusing on brain metastasis and leptomeningeal disease. The importance of enrolling patients in clinical trials is emphasized. Rugo discusses individualizing neoadjuvant therapy and potential strategies for trastuzumab deruxtecan (T-DXd) maintenance. O’Shaughnessy addresses the challenge of treating de novo metastatic cases and the necessity for chronic therapies. The panel collectively advocates for ongoing research and patient-centric care. The discussion provides valuable insights into the evolving landscape of HER2-positive breast cancer treatment.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
